Invivyd

Historical price data

Invivyd is on a mission to rapidly and continually deliver antibody-based therapies that keep pace with evolving viral threats, starting with COVID-19. The company employs a unique, integrated technology platform to develop best-in-class antibodies that are more potent and resistant to virus evolution than the natural immune response. Its strategic focus includes building a robust pipeline for prevention and treatment, with a lead asset authorized for emergency use and a Phase 3 candidate showing positive results. The leadership team comprises seasoned executives with deep experience in infectious disease drug development and commercialization.

A proprietary integrated platform that pairs state-of-the-art viral surveillance and predictive modeling with advanced antibody engineering to rapidly develop monoclonal antibodies that are more potent and resistant to virus evolution than the human immune system.

7 drugs in pipeline, 4 in Phase 3

Invivyd competes with large pharma (e.g., AstraZeneca, Eli Lilly, Regeneron) and other biotechs in the antiviral antibody space. Its main differentiation is its integrated platform focused on speed and engineering for variant resistance. However, it faces significant challenges in out-executing well-resourced competitors in a scientifically and commercially dynamic field.